To examine the antitumor effects of afatinib on the NSCLC cell lines without EGFR mutation, we conducted FACS analysis by flow cytometry using propidium iodide (PI) to analyze the sub-G1 percentage. This evidence concerns the gene EGFR and non-small cell lung carcinoma.